MnO2-CNO Nanocomplex for Hypoxic Tumor Microenvironment Normalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer therapies face challenges in effectively targeting tumor hypoxia, which confers chemotherapeutic resistance and reduces the efficacy of radio-sensitization, due to the poor penetration of drugs and oxygen depletion in solid tumors, leading to reduced therapeutic outcomes.
Innovation Solution
A tumor microenvironment-responsive nanocomplex comprising manganese dioxide (MnO2) sheets embedded with carbon nano-onions (CNOs) that modulates hydrogen peroxide levels, producing oxygen to normalize the hypoxic environment and enhance photothermal therapy by inhibiting hypoxia-inducible factor (HIF1-α) and sensitizing tumor cells to treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy and radiotherapy are used to treat solid tumors, then cancer cells can be targeted, but tumor hypoxia causes poor drug penetration and reduces therapeutic efficacy
Solution Approach 1:
The patent utilizes the excess hydrogen peroxide (H2O2) secreted by cancer cells under hypoxic conditions as a beneficial resource. The MnO2 nanocomplex catalyzes H2O2 decomposition to generate oxygen in situ, converting the harmful hypoxic environment into a normoxic one that enhances chemotherapy and radiotherapy efficacy
Solution Approach 2:
The patent changes the oxygen concentration parameter in the tumor microenvironment by using MnO2-catalyzed H2O2 decomposition. This parameter change transforms the hypoxic state (low oxygen) into a normoxic state (normal oxygen), thereby improving drug penetration and therapeutic response
2Reliability
If tumor hypoxia is present in solid tumors, then cancer cell survival is promoted, but chemotherapeutic drug penetration is poor
Solution Approach 1:
The patent converts the harmful hypoxic environment into a beneficial normoxic environment by catalyzing H2O2 decomposition. The generated oxygen improves drug penetration and eliminates the protective effect of hypoxia on cancer cells
Solution Approach 2:
The MnO2 nanocomplex acts as an intermediary that facilitates the conversion of H2O2 to oxygen. This intermediary material enables the transformation of the tumor microenvironment from hypoxic to normoxic, thereby improving drug penetration without directly modifying the drugs themselves
3Reliability
If hydrogen peroxide is secreted excessively by cancer cells, then hypoxic conditions are maintained, but the nanocomplex can modulate this disproportion
Solution Approach 1:
The patent converts the excessive H2O2 secretion (harmful for maintaining hypoxia) into a beneficial source of oxygen. The MnO2 catalyst transforms H2O2 decomposition from a harmful process into a useful oxygen-generating reaction that normalizes the tumor microenvironment
Solution Approach 2:
The patent employs the cancer cells' own secreted H2O2 as the substrate for oxygen generation. The nanocomplex utilizes the endogenous H2O2 produced by tumor cells themselves, eliminating the need for external oxygen supply or additional reagents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanocomplex effectively transforms hypoxic tumor microenvironments into normoxic conditions, suppressing cancer cell proliferation, potentiating therapeutic efficacy, and inhibiting tumor recurrence and metastasis through enhanced oxygen supply and catalase-mimicking activity.
Implementation Method 1
The nanocomplexes of the present disclosure produce oxygen through catalase-mimicking activity when exposed to hydrogen peroxide in the tumor-microenvironments
Implementation Method 2
carbon nano-onions (CNOs) embedded in the manganese dioxide sheet
Data Source
AI summary
Various embodiments of the present disclosure are to provide a tumor microenvironment-responsive nanocomplex capable of presenting a novel paradigm for tumor therapy by reprogramming tumor microenvironments and an anticancer composition containing the same.